Your session is about to expire
← Back to Search
Retifanlimab Combination Therapy for Endometrial Cancer (POD1UM-204 Trial)
POD1UM-204 Trial Summary
This trial is testing a new drug, retifanlimab, for endometrial cancer that has progressed after platinum-based chemotherapy. It will be given as monotherapy or in combination with other immunotherapy or targeted agents.
POD1UM-204 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPOD1UM-204 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.POD1UM-204 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine in the last 28 days.My tumor is MMR deficient or has a POLE mutation.My cancer has grown despite previous PD-1 or PD-L1 therapy and my tumor is MSI-H.My tumor is MSI-High.My side effects from previous treatments have mostly gone away.I have never been treated with a PD-(L)1 inhibitor.I am taking high doses of steroids or other drugs for an autoimmune disease.You are not planning to get pregnant during the study.My endometrial cancer has worsened after treatment with a platinum-based therapy.My tumor is MSS and tests positive for PD-L1.I can carry out all my daily activities without help.I understand the study and agree to participate.My condition may be treatable with the intent to cure.I haven't had cancer treatment in the last 28 days, except for targeted radiation.My cancer is a type of uterine sarcoma confirmed by tissue analysis.I've had LAG-3, TIM-3, or lenvatinib treatment and mixed results from anti-PD-(L)1 therapy for my multiple metastases.I am taking more than 10 mg/day of prednisone or its equivalent.I have active hepatitis B or C.I have lung scarring or inflammation not caused by an infection.My tumor has an FGFR 1,2,3 mutation.I have cancer that has spread to my brain or surrounding membranes.I experienced limited side effects from previous immune therapy.My diagnosis is carcinosarcoma of the uterus.
- Group 1: Group A - retifanlimab
- Group 2: Group B - retifanlimab
- Group 3: Group C - retifanlimab + epacadostat
- Group 4: Group D - retifanlimab + pemigatinib
- Group 5: Group E - retifanlimab + epacadostat
- Group 6: Group F - retifanlimab + INCAGN02385 and INCAGN02390
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any unoccupied slots available for this clinical experiment?
"Affirmative. Clinicaltrials.gov's records attest to this ongoing medical trial, which was published on January 26th 2021 and most recently revised in November of 2022. The study needs around 300 participants from 27 different sites for completion."
What are the primary indications for retifanlimab treatments?
"Retifanlimab can be implemented to treat unresectable, metastatic cholangiocarcinomas, advance directives and fgfr2 protein in human patients."
Could you please elucidate the safety of retifanlimab for individuals?
"With some clinical evidence supporting its safety, retifanlimab earned a score of 2. It should be noted that no prior data exists in regards to the efficacy of this drug for humans."
What is the current enrollment size of this medical experiment?
"Affirmative. The records published on clinicaltrials.gov illustrate that this research is actively recruiting participants, having first been made available to the public on January 26th 2021 and was last edited on November 11th 2022. Altogether 300 patients need to be enrolled across 27 sites."
Has retifanlimab been the subject of other research experiments?
"Currently, there are 46 clinical trials investigating retifanlimab with 6 in the final phase of research. While Istanbul and California boast a majority of these studies, 1585 different locations across the world have opened their doors to this drug's investigation."
How many sites are participating in the execution of this trial?
"Patients are currently being recruited from Advent Health Medical Group-Orlando 2501, Texas Oncology the Woodlands in Shenandoah and Tennessee Oncology in Nashville. Additionally, there are 27 other medical centres hosting this trial."
Share this study with friends
Copy Link
Messenger